Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 9/20 | 0.90 |
| ▸ | PTGS2 | P35354 | 12/20 | 0.90 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.79 |
| ▸ | PTGES | O14684 | 1/20 | 0.77 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.77 |
| ▸ | CA12 | O43570 | 1/20 | 0.77 |
| ▸ | PDE5A | O76074 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.77 |
| ▸ | CA1 | P00915 | 1/20 | 0.77 |
| ▸ | CA2 | P00918 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | CA3 | P07451 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5923919 | 0.95 | PDPK1 (1.00) | PDPK1PTGS2PTGS1CYP2C9PTGES | |
| SCHEMBL213784 | 0.95 | PTGS2 (1.00) | PDPK1PTGS2PTGS1CYP2C9PTGES | |
| SCHEMBL6342351 | 0.93 | PTGS2 (0.90) | PDPK1PTGS2PTGS1CYP2C9PTGES | |
| Sulfamide SCHEMBL7139961 | 0.91 | PTGS1 (0.83) | PDPK1PTGS2PTGS1CYP2C9PTGES | |
| Dimethylamine SCHEMBL7651697 | 0.90 | PTGS2 (0.91) | PDPK1PTGS2PTGS1CYP2C9PTGES | |
| SCHEMBL5673420 | 0.90 | PDPK1 (1.00) | PDPK1PTGS2PTGS1CYP2C9PTGES | |
| SCHEMBL3246379 | 0.88 | PTGS2 (1.00) | PDPK1PTGS2PTGS1CYP2C9PTGES | |
| Mavacoxib SCHEMBL212699 | 0.88 | PTGS2 (1.00) | PDPK1PTGS2PTGS1CYP2C9PTGES | |
| SCHEMBL3096416 | 0.88 | PTGS2 (1.00) | PDPK1PTGS2PTGS1CYP2C9PTGES | |
| SCHEMBL152885 | 0.88 | PTGS2 (1.00) | PDPK1PTGS2PTGS1CYP2C9PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1520324-A | Antiangiogenic combination thereapy for treatment of cancer | — | 2004-08-11 | — | — | CN | claimed |
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | claimed |
| EP-1377298-A2 | COMBINED METHOD FOR TREATING HORMONO-DEPENDENT DISORDERS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | claimed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| CN-1371286-A | Use of cyclooxygenase-2 inhibitor matrix metallappoteinase inhibitor antineoplastic agent and optionally radiation as combination treatment of neoplasia | SEARLE & CO (US) | 2002-09-25 | — | — | CN | claimed |
| WO-2002072106-A2 | COMBINED METHOD FOR TREATING HORMONO-DEPENDENT DISORDERS WITH EXEMESTANE | PHARMACIA ITALIA SPA (IT) | 2002-09-19 | — | — | WO | claimed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | claimed |
| CN-1346282-A | Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as combination therapy method in treating neoplasia | SEARLE & CO (US) | 2002-04-24 | — | — | CN | claimed |
| EP-1140192-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| EP-1140194-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINED TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| EP-1140179-A2 | USE OF A CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038730-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000038786-A2 | USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000037107-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINATION TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-06-29 | — | — | WO | claimed |
| US-20260027079-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | EPM IP INC (US) | 2026-01-29 | — | — | US | disclosed |
| CN-118831076-A | Cannabinoid acid ester compositions and uses thereof | EPM (IP)公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-113840598-B | Cannabinoid acid ester compositions and uses thereof | EPM (IP)公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | disclosed |
| WO-1995015317-A1 | 1,4,5-TRIPHENYL PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION AND INFLAMMATION-RELATED DISORDERS | G.D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | PDPK1 2377/4885PTGS2 4/4885PTGS1 6/4885 |
| US-20260027079-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | CNR2, CNR1, FAAH | PDPK1 499/4885PTGS2 2555/4885PTGS1 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.